UK Markets closed

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2614-0.0026 (-0.98%)
At close: 03:35PM EST

Kiromic BioPharma, Inc.

7707 Fannin
Suite 140
Houston, TX 77054
United States
832 968 4888

Full-time employees59

Key executives

NameTitlePayExercisedYear born
Mr. Pietro Bersani CPA, J.D.CEO & Director167.76kN/A1968
Dr. Scott Dahlbeck M.D., Pharm.D., PharmDChief of Staff442.12kN/A1962
Mr. Daniel ClarkChief Financial OfficerN/AN/A1989
Dr. Leonardo Mirandola Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Michael Ryan Ph.D.Chief Bioinformatics Research Computing OfficerN/AN/A1967
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Corporate governance

Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.